N-Acetyl-Calicheamicin is primarily utilized in the field of targeted cancer therapy, particularly in the development of antibody-drug conjugates (ADCs). Its potent cytotoxic properties make it an effective payload in ADCs, where it is attached to monoclonal antibodies that specifically target cancer cells. Once the ADC binds to the cancer cell, N-Acetyl-Calicheamicin is internalized and released, inducing DNA damage and ultimately leading to cell death. This targeted approach minimizes damage to healthy tissues, making it a valuable component in treatments for certain types of cancers, such as acute myeloid leukemia (AML). Its application represents a significant advancement in precision medicine, offering a more effective and less toxic alternative to traditional chemotherapy.